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Abstract: To report the possibility of post myopic photorefractive keratectomy (PRK) haze treatment in a patient with 
expressed reluctance for any additional laser therapy. Seven months after bilateral PRK with subsequent development of 
corneal haze and refractive regression in both eyes, a 37-old-year male patient presented a best-spectacle corrected visual 
acuity (BSCVA) of 20/30 in the right eye and of 20/22 in the left eye. Both eyes were sequentially treated by scraping the 
stromal surface and application of mitomycin C (MMC) for 2 minutes. Both eyes had significant improvement in corneal 
transparency. Eighteen months after this treatment BSCVA had improved to 20/20 in each eye. No toxic effects were 
observed during either re-epithelialization or follow-up periods. In conclusion scraping and application of MMC could be 
considered a good tool in the treatment of selected cases of haze after myopic PRK, especially with patients that are 
reluctant to undergo a secondary laser procedure. 
Keywords: Mitomycin C, Haze, PRK, Scraping. 
INTRODUCTION 
  Excimer laser photorefractive keratectomy has proven to 
be a safe and an effective technique to correct mild to 
moderate refractive errors. Haze formation with loss of 
corneal transparency, formation of surface irregularities, and 
myopic regression are the major complications after surface-
based corneal refractive surgery. There are several medical 
and surgical methods of managing haze. Initially the haze 
can be treated with topical steroids and topical non-steroidal 
anti-inflammatory drugs, especially in myopic eyes, but their 
efficacy over a long-time period is still controversial as they 
may also increase intraocular pressure (IOP) [1]. Haze can 
be treated with mechanical epithelial debridement or with 
laser-scrape [2]. Success of these procedures may depend on 
the morphology of the haze and on the patient’s individual 
wound healing response. Manual debridement coupled with 
phototherapeutic keratectomy and mitomycin-C (MMC) can 
also be performed [3]. We present a case of a patient with a 
dense, visually significant reticular haze that developed 
approximately 3 months after myopic PRK. This patient also 
expressed reluctance for any additional laser therapy. This 
patient was treated by scraping the stromal surface to 
manually remove the irregular corneal tissue, followed by 
application of a diluted MMC solution on the stromal 
surface, to prevent further haze formation. 
CASE REPORT 
  A 37-old-year male patient was seen who had received 
primary, bilateral PRK treatments by a surgeon using an 
InPro GmbH (Norderestadt, Germany) excimer laser to 
correct a refractive error of -5.50=-1.50-X-180 in the right 
eye (RE) and -6.25 sphere in the left eye (LE). Seven months  
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after the initial treatment, the patient presented complaining 
of a reduction of the quality and quantity of visual acuity. 
  A complete ophthalmologic examination was performed 
with the RE showing uncorrected visual acuity (UCVA) of -
20/400 and best spectacle-corrected visual acuity (BSCVA) 
of 20/30 with a manifest refraction of -3.00=-1.50 -X-180. 
The LE had UCVA of 20/400 and a BSCVA of 20/22 with a 
manifest refraction of -4.00 sphere. The biomicroscopy 
examination showed an anterior stromal haze of grade 4 in 
both eyes (using the Heitzmann criteria (from 0 to 5)-(Fig. 
1A). The computerized videokeratography using a 
Keratograph (Oculus Optikgeräte GmbH, Wetzlar, Germany) 
showed evidence of irregular astigmatism (Fig. 2A). 50 MHz 
ultrasound pachymetry (Corneo-Gage Plus
TM, Sonogage Inc., 
Cleveland, USA) elicited a minimum central corneal 
thickness of 583 m in the RE and of 582 m in the LE. 
Noncontact endothelial specular microscopy (Seed SP500, 
Seed Co., Tokyo, Japan) provided an endothelial cells 
density of 2882 cells/mm
2 in RE and 2760 cells/mm
2 in the 
LE. The scotopic pupil, evaluated by infrared pupillometry 
(Colvard, Oasis, Glendora, California, USA), was 5.5 mm in 
both eyes. Intraocular pressure, using Goldmann applanation 
tonometry, was 16 mmHg in each eye. Fundus examination 
was within normal limits. The patient was reluctant to 
undergo a new laser treatment and therefore a bilateral, 
sequential, non-laser therapy was planned. 
  After obtaining appropriate informed consent, the 
treatments were performed using topical anesthesia with 
oxybuprocaine 0.4% drops and a sterile eyelid speculum was 
placed in the operative eye. Using a Desmarres corneal knife 
(Medtronic Ophthalmics, Jacksonville, Florida, USA), the 
epithelium was removed and then the corneal surface was 
scraped to remove as much scar as possible. Topical 
administration of 0.2 mg/ml mitomycin-C (MMC) diluted in 
balanced salt solution was then made by placing an 8-mm-
diameter Hoffer Optic Zone Marker (Katena Products Inc., 
Denville, New Jersey, USA) onto the cornea. The solution 64    The Open Ophthalmology Journal, 2011, Volume 5  Spadea and Verrecchia 
was maintained in place for 2 minutes and then removed. 
The corneal surface and entire conjunctival sac were then 
vigorously irrigated using balanced salt solution (BSS Plus, 
Alcon Laboratories, Fort Worth, Texas, USA) to remove all 
MMC. After the treatment, a soft contact lens was applied as 
a bandage and a topical antibiotic agent (ofloxacin 0.3%) and 
artificial tear drops (preservative free sodium hyaluronate 
0.20%) were applied until re-epithelialization was completed 
(6 days). Topical corticosteroids (butyrate clobetasone 0.1%) 
drops were administered for 3 months and then tapered and 
titrated. Follow-up examinations were scheduled at 1, 3, 6, 
12 and 18 month after treatment. No side effects or toxic 
effects were detected during the follow-up period. 
  After eighteen months from the scraping and MMC 
application, the biomicroscopy evaluation showed clear 
corneas (haze grade 0.5) (Fig. 1B), and an associated low 
physiologic astigmatism in both eyes (Fig. 2B). The UCVAs 
were 20/32 and 20/100 respectively in RE and in LE, and the 
BSCVAs were 20/20 in both eyes (RE -1.75sph and LE -
3.25sph). The central corneal thickness decreased to 546 m 
in the RE and to 569 m in the LE. The endothelial cell 
count was unchanged (2804 cells/mm
2  in RE and 2755 
cells/mm
2 in LE). The patient reported an improved quality 
of visual acuity, and was satisfied with the results of the 
remediation. 
DISCUSSION 
  Although PRK has proven to be safe and effective for a 
limited range of ametropias, use for correction of higher 
amounts of refractive error can lead to errant tissue reactions, 
which in turn can lead to corneal opacity and scar formation, 
called haze. In fact, although the technology has improved 
and some of the risk factors are now well known, haze 
remains the major complication after PRK. Corneal haze 
evidenced after an excimer laser treatment is characterized 
by disorganized sub-epithelial neocollagen constituted ex-
novo by mucuspolysaccharides and glycosamminoglicans 
synthesized by activated keratocytes [4]. The haze formation 
could consequently cause hypocorrection, astigmatism and 
myopic regression that may require retreatment. 
 Vigo  et al. explored the possibility of treating haze by 
use of a cytostatic drug, mitomycin-C, after scraping the 
corneal surface to remove the corneal irregularity [5]. 
Applied on the cornea, mitomycin-C did not result in 
increased loss of keratocytes, but it significantly delayed 
keratocyte repopulation and activation in the anterior stroma 
with normal epithelial differentiation [6]. For these reasons 
MMC is a potent inhibitor of corneal scar formation (haze) 
induced by PRK. 
  The first phase of the technique used in the present case, 
scraping, must be vigorous and continuous until the corneal 
surface appears smoother and more homogeneous. In the 
second step, we administered the MMC in a new mode, by 
filling an 8-mm-diameter optic zone marker placed onto the 
cornea. This technique provides tighter contact of the 
solution to the stroma than by use of a Merocel sponge 
soaked with MMC. A proper dilution of the drug is crucial 
with the standard concentration of topical MMC (0.02%) 
being more effective than a lower dose (0.002%) in 
preventing postoperative haze following surface ablation for 
high myopia, without inducing any serious complications. 
The duration of MMC exposure appears to be less important 
than its concentration [7]. If the concentration is too high, the 
MMC may be toxic, producing opacity and corneal melting 
[8]. Administration of 0.02% MMC applied for 12 seconds 
following PRK did not have a significant effect on 
quantitative endothelial cell density or qualitative 
morphometric parameters [9]. To the contrary, in a 
nonrandomized controlled trial, Nassiri et al. noted that the 
prophylactic use of diluted intraoperative MMC 0.02% 
solution caused corneal endothelial cell loss [10]. 
  The present clinical case showed no side effects and 
corneal transparency has been maintained with no recurrence 
of haze for an extended period of 18 months. Therefore 
scraping and application of MMC could be considered a 
good tool for the treatment of selected cases of haze after 
myopic PRK, especially with patients that are reluctant to 
undergo a secondary laser procedure. 
 
 
 
Fig. (1). Right eye slit lamp photographs before (A) and 18 months after (B) scraping of the stromal surface and application of MMC for 
treatment of post-PRK haze. The corneal clarity has remarkably improved. Effectiveness of Scraping and Mitomycin C to Treat Haze  The Open Ophthalmology Journal, 2011, Volume 5    65 
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Fig. (2). Right eye videokeratography maps before (A) and 18 months after (B) scraping of the stromal surface and application of MMC for 
treatment of post-PRK haze. The topographic pattern highlights the improved corneal profile obtained (relative scale, tangential algorithm). 